Email Page Print Page

Corporate Governance *



BDSI® Code of Ethical Conduct

On March 24, 2003, BDSI®'s Board of Directors adopted the Code of Ethical Conduct for the company's principal executive and financial officers. (revision: April 2014)


BDSI® Disclosure Policy

BioDelivery Sciences International, Inc. is committed to the fair disclosure of information about the company consistent with the Securities and Exchange Commission's Regulation Fair Disclosure ("Regulation FD").


Audit Committee Charter - Amended July 2014


Nominating and Corporate Governance Committee Charter - Adopted May 19, 2004 


Compensation Committee Charter - Amended July 2014


Lead Director Charter - Adopted July 26, 2007



* Each of our Board committees reviews its charter for potential updates on an annual basis.  In addition, our Board of Directors reviews our company's Code of Ethical Conduct for potential updates on an annual basis.

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces FDA Approval of New Formulation of ONSOLIS® (fentanyl buccal soluble film) CII
Approval of new formulation expected to allow ONSOLIS to return to U.S. market in 2016

BioDelivery Sciences Strengthens Sales Force Leadership with Hiring of Scott Plesha, Former Salix Head of Sales
Plesha to Lead BUNAVAIL Sales Effort; Joins BDSI Following 13 years in Building and Managing the Salix GI Sales Force